Get the Stockscreener App
25.02
2.12%
0.52
After Hours:
25.52
0.50
+2.00%
Ideaya Biosciences Inc stock is traded at $25.02, with a volume of 1.88M.
It is up +2.12% in the last 24 hours and up +17.08% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$24.50
Open:
$25.18
24h Volume:
1.88M
Relative Volume:
1.59
Market Cap:
$2.19B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.42
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+14.72%
1M Performance:
+17.08%
6M Performance:
+4.86%
1Y Performance:
-40.98%
1-Day Range:
$24.76
$26.15
1-Week Range:
$21.50
$26.15
52-Week Range:
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
25.02 | 2.15B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Chart based analysis of IDEAYA Biosciences Inc. trendsFree Fast Gaining Stock Screener Report - Newser
Historical volatility pattern of IDEAYA Biosciences Inc. visualizedProven Trading System with Consistent Gains - Newser
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionFree Price Action Based Buy Opportunity List - Newser
Can IDEAYA Biosciences Inc. rally from current levelsSwing Entry Insight With Forecast Accuracy - Newser
Analyzing net buyer seller activity in IDEAYA Biosciences Inc.Trade Flow Monitor with Volume Tracker - Newser
Evaluating IDEAYA Biosciences Inc. with trendline analysisDaily Pick Forecast with Entry Zones - Newser
What catalysts could drive IDEAYA Biosciences Inc. stock higher in 2025Unlock daily market insights for better decisions - jammulinksnews.com
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockHigh-margin investment plays - jammulinksnews.com
How volatile is IDEAYA Biosciences Inc. stock compared to the marketCapitalize on momentum-driven investment opportunities - jammulinksnews.com
Will IDEAYA Biosciences Inc. stock benefit from AI tech trendsFree AI-Powered Stock Predictions - Metal.it
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Invest smarter with data-backed trading alerts - jammulinksnews.com
What drives IDEAYA Biosciences Inc. stock priceSignificant capital appreciation - PrintWeekIndia
TD Cowen Bullish on Ideaya’s (IDYA) Oncology Pipeline - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Research Coverage Started at TD Cowen - Defense World
What analysts say about IDEAYA Biosciences Inc. stockTriple-digit profit margins - PrintWeekIndia
Is IDEAYA Biosciences Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia
What makes IDEAYA Biosciences Inc. stock price move sharplyFree Investing Community - Newser
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - The Malaysian Reserve
IDEAYA to present phase 2 data on uveal melanoma drug at ESMO - Investing.com Australia
IDEAYA to present phase 2 data on uveal melanoma drug at ESMO By Investing.com - Investing.com South Africa
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy - Nasdaq
IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest
IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan
Signaturefd LLC Increases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - The Malaysian Reserve
IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - TipRanks
Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest
Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks
TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada
TD Cowen Initiates Coverage of IDEAYA Biosciences (IDYA) with Buy Recommendation - MSN
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event - WV News
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):